Good MorningEquity markets ended the week, month and year on a sour note falling more than 1.0% at the low of the day on Friday to cap off a year of selling in the stock market. The S&P 500 shed more than 25% at the depths of the correction and may reach those levels again in 2023. The risk for the market this year is not only a worsening outlook for corporate earnings but a growing possibility for a deep recession.
This week may be another week of listless trading but the action will heat up soon enough. The calendar Q4 2022 earnings reporting season begins with releases from JPMorgan and other major banks along with key reports from other sectors. As it is, the market is expecting to see S&P 500 earnings fall by roughly 3.0% on average which will be the first decline in earnings since the depths of the pandemic in Q3 of 2020. Featured: Author of Get Rich with Dividends Is Giving Away His Ultimate Dividend Package FOR FREE! (The Oxford Club) 
|
Markets | | |
At first glance, it might seem like Kintara Therapeutics Inc (Nasdaq: KTRA) would not be a good investment. After all, analysts gave the stock a HOLD rating after its Q3 earnings report in November. However, that rating alone is not enough to understand the full scope of possibility in its future,... Read the Full Story |
|
From Our PartnersThis hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing. | | Click here to get this secret |
|
Markets | | |
2022 has been challenging for big tech. While the QQQ NASDAQ Index tracking stock (NYSE: QQQ) is down more than 33% from its post-pandemic peak names like Facebook (cough Meta Platforms (NASDAQ: META)), Amazon (NASDAQ: AMZN) and Salesforce.com (NYSE: CRM) are down more than 50%, and the figure may... Read the Full Story |
|
Stocks | | |
This article highlights three high-yield dividend stocks that investors will want to consider buying in 2023. Investors are expecting another volatile year. And owning dividend stocks is a time-honored way to stay invested during market volatility.
Because these companies pay shareholders ... Read the Full Story |
|
From Our PartnersClick Here to Get Marc Lichtenfeld's Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 9% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. | | | | For Free. |
|
Tech | | | Wall Street capped a quiet day of trading with more losses Friday, as it closed the book on the worst year for the S&P 500 since 2008.
The benchmark index finished with a loss of 19.4% for 2022, or 18.1%, including dividends. It's just its third annual decline since the financial... Read the Full Story |
|
Tech | | | Shares began the year mixed on Monday, with most markets closed for New Year holidays.
This week brings employment data and minutes from the latest meeting of the Federal Reserve as it battles inflation. That will likely remain investors’ overarching concern as 2023 begins with persi... Read the Full Story |
|
From Our PartnersMorgan Stanley is warning of an "imminent recession" in Europe. The head of the European Central Bank says it is a "very dark downside scenario."
And one Virginia millionaire who predicted the housing crisis and called the bottom of the COVID market... says this could be devastating to U.S. stocks.
But only if ONE THING doesn't happen. | | | | See his shocking prediction here. |
|
Markets | | | Stocks fell in afternoon trading on Wall Street Friday as major indexes close out a dismal year with lingering concerns about stubbornly hot inflation and a potential recession.
The S&P 500 fell 0.8% as of 3:13 p.m. Eastern. The index, which is considered a benchmark for the broad... Read the Full Story |
|
Markets | | |
Power generation and energy storage systems maker Generac Holdings Inc. (NASDAQ: GNRC) stock has been a heartbreaker. Shares were trading at a high of $524.31 just over a year ago before shares fell to a new weekly lower low of $86.29 in late December, falling below its pre-pandemic levels.
With ... Read the Full Story |
|
Markets | | | Democrats in Congress released thousands of pages of former President Donald Trump's tax returns Friday, providing the most detailed picture to date of his finances over a six-year period, including his time in the White House, when he fought to keep the information private in a break with decades o... Read the Full Story |
|
Markets | | | India’s top court said Monday that the government’s surprise decision in 2016 to demonetize high-value bills was legal and taken after consultation with India's central bank.
The five-judge constitution bench was hearing petitions challenging the currency ban that rendered 86% of Indi... Read the Full Story |
|
Markets | | |
Microsoft Corporation (NASDAQ: MSFT) scooped up a 4% stake in the London Stock Exchange Group (LON: LSEG) this month. Investors might wonder what significance this will have for the company moving forward.
As part of the acquisition, the companies will work to create a "centralized, financia... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
